Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
2021 | Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan | Huang C.-F.; Kuo H.-T.; Chang T.-S.; Lo C.-C.; Hung C.-H.; Huang C.-W.; Chong L.-W.; Cheng P.-N.; Yeh M.-L.; Peng C.-Y.; Cheng C.-Y.; Huang J.-F.; Bair M.-J.; Lin C.-L.; Yang C.-C.; Wang S.-J.; Hsieh T.-Y.; Lee T.-H.; Lee P.-L.; Wu W.-C.; Lin C.-L.; Su W.-W.; Yang S.-S.; Wang C.-C.; Hu J.-T.; Mo L.-R.; Chen C.-T.; Huang Y.-H.; Chang C.-C.; Huang C.-S.; Chen G.-Y.; Kao C.-N.; Tai C.-M.; CHUN-JEN LIU ; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; JIA-HORNG KAO ; Lin H.-C.; Chuang W.-L.; Chen C.-Y.; Tseng K.-C.; Yu M.-L. | Scientific Reports | 9 | 5 | |
2021 | A novel deep intronic variant strongly associates with Alkaptonuria | Lai C.-Y.; I-JUNG TSAI ; Chiu P.-C.; Ascher D.B.; YIN-HSIU CHIEN ; Huang Y.-H.; Lin Y.-L.; WUH-LIANG HWU ; NI-CHUNG LEE | npj Genomic Medicine | 5 | 5 | |
2014 | A nucleolus-predominant piggyBac transposase, NP-mPB, mediates elevated transposition efficiency in mammalian cells | JIN-BON HONG ; Chou F.-J.; Ku A.T.; Fan H.-H.; Lee T.-L.; Huang Y.-H.; TSUNG-LIN YANG ; Su I.-C.; Yu I.-S.; SHU-WHA LIN ; CHUNG-LIANG CHIEN ; HONG-NERNG HO ; YOU-TZUNG CHEN | PLoS ONE | 4 | 4 | |
2020 | An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients with Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions | Huang C.-F.; Hung C.-H.; Cheng P.-N.; Bair M.-J.; Huang Y.-H.; JIA-HORNG KAO ; SHIH-JER HSU ; Lee P.-L.; Chen J.-J.; Chien R.-N.; Peng C.-Y.; Lin C.-Y.; Hsieh T.-Y.; Cheng C.-H.; Dai C.-Y.; Huang J.-F.; Chuang W.-L.; Yu M.-L. | Journal of Infectious Diseases | 15 | 11 | |
2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | Chen L.-T.; Martinelli E.; ANN-LII CHENG ; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; CHIUN HSU ; YING-CHUN SHEN ; Tabernero J.; Yen Y.; CHIH-HUNG HSU ; Yoshino T.; Douillard J.-Y. | Annals of Oncology | 117 | 112 | |
2021 | Perception of the threat, mental health burden, and healthcare-seeking behavior change among psoriasis patients during the COVID-19 pandemic | HSIEN-YI CHIU ; Liao N.-F.C.; Lin Y.; Jr.; Huang Y.-H. | PLoS ONE | 0 | 0 | |
2018 | Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B | Hsu C.-W.; Su W.-W.; Lee C.-M.; Peng C.-Y.; Chuang W.-L.; JIA-HORNG KAO ; Chu H.-C.; Huang Y.-H.; Chien R.-N.; Liaw Y.-F. | Journal of the Formosan Medical Association | 20 | 17 | |
2010 | PINT: Pathways integration tool | Wang Y.-T.; Huang Y.-H.; Chen Y.-C.; CHIA-LANG HSU ; Yang U.-C. | Nucleic Acids Research | 7 | 8 | |
2009 | Pluripotency of mouse spermatogonial stem cells maintained by IGF-1- Dependent pathway | Huang Y.-H.; Chin C.-C.; Ho N.-N.; Chou C.-K.; Shen C.-N.; Kuo H.-C.; Wu T.-J.; Wu Y.-C.; Hung Y.-C.; Chang C.-C.; THAI-YEN LING | FASEB Journal | 97 | 89 | |
2022 | Potential of Cellular Therapy for ALS: Current Strategies and Future Prospects | Lin T.-J.; Cheng G.-C.; Wu L.-Y.; Lai W.-Y.; THAI-YEN LING ; Kuo Y.-C.; Huang Y.-H. | Frontiers in Cell and Developmental Biology | 4 | 6 | |
2009 | Potential predictors of motor and functional outcomes after distributed constraint-induced therapy for patients with stroke | KEH-CHUNG LIN ; Huang Y.-H.; Hsieh Y.-W.; Wu C.-Y. | Neurorehabilitation and Neural Repair | 45 | 44 | |
2010 | Predictors of change in quality of life after distributed constraint-induced therapy in patients with chronic stroke | Huang Y.-H.; Wu C.-Y.; Hsieh Y.-W.; KEH-CHUNG LIN | Neurorehabilitation and Neural Repair | 27 | 25 | |
2016 | Predilection of contralateral upper lung metastasis in upper lobe lung adenocarcinoma patients | Huang Y.-H.; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; KANG-YI SU ; Chen H.-Y.; Chang C.-S.; Chen J.J.W.; SUNG-LIANG YU ; HUEI-WEN CHEN ; Yang T.-Y.; Chang G.-C. | Journal of Thoracic Disease | 2 | 2 | |
2011 | Prioritizing disease candidate genes by a gene interconnectedness-based approach | CHIA-LANG HSU ; Huang Y.-H.; Hsu C.-T.; Yang U.-C. | 10th Int. Conference on Bioinformatics - 1st ISCB Asia Joint Conference 2011, InCoB 2011/ISCB-Asia 2011: Computational Biology - Proceedings from Asia Pacific Bioinformatics Network (APBioNet) | 35 | 32 | |
2018 | Prognostic factors of health care–associated bloodstream infection in adult patients ≥40 years of age | Ma H.-Y.; Hung I.-C.; Huang Y.-H.; Chang Y.-Y.; WANG-HUEI SHENG ; JANN-TAY WANG ; WEI-CHU CHIE ; Liu J.-P.; YEE-CHUN CHEN | American Journal of Infection Control | 7 | 7 | |
2018 | Quick screening tool for patients with severe negative emotional reactions to chronic illness: Psychometric study of the negative emotions due to chronic illness screening test (NECIS) | Huang Y.-H.; Wu C.-H.; Chen H.-J.; Cheng Y.-R.; Hung F.-C.; Leung K.-K.; Lue B.-H.; Chen C.-Y.; TAI-YUAN CHIU ; Wu Y.-C. | Family Practice | 1 | 2 | |
2019 | Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study | CHEN-HUA LIU ; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 8 | 8 | |
2008 | Recurrent advancing wavelike epitheliopathy from the opposite side of the initial presentation | Huang Y.-H.; HSIAO-SANG CHU ; FUNG-RONG HU ; I-JONG WANG ; YU-CHIH HOU ; WEI-LI CHEN | Cornea | 5 | 4 | |
2017 | A recurrent WARS mutation is a novel cause of autosomal dominant distal hereditary motor neuropathy | Tsai P.-C.; Soong B.-W.; Mademan I.; Huang Y.-H.; Liu C.-R.; Hsiao C.-T.; Wu H.-T.; Liu T.-T.; Liu Y.-T.; Tseng Y.-T.; Lin K.-P.; Yang U.-C.; Chung K.W.; Choi B.-O.; Nicholson G.A.; Kennerson M.L.; CHIH-CHIANG CHAN ; De Jonghe P.; Cheng T.-H.; Liao Y.-C.; Züchner S.; Baets J.; Lee Y.-C. | Brain | 70 | 64 | |
2017 | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Bruix J.; Qin S.; Merle P.; Granito A.; Huang Y.-H.; Bodoky G.; Pracht M.; Yokosuka O.; Rosmorduc O.; Breder V.; Gerolami R.; Masi G.; Ross P.J.; Song T.; Bronowicki J.-P.; Ollivier-Hourmand I.; Kudo M.; ANN-LII CHENG ; Llovet J.M.; Finn R.S.; LeBerre M.-A.; Baumhauer A.; Meinhardt G.; Han G. | The Lancet | 2620 | 2396 | |